Michael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, Francesco Buccisano, Christopher S Hourigan, Lok Lam Ngai, Jesse M Tettero, Costa Bachas, Constance Baer, Marie-Christine Béné, Veit Bücklein, Anna Czyz, Barbara Denys, Richard Dillon, Michaela Feuring-Buske, Monica L Guzman, Torsten Haferlach, Lina Han, Julia K Herzig, Jeffrey L Jorgensen, Wolfgang Kern, Marina Y Konopleva, Francis Lacombe, Marta Libura, Agata Majchrzak, Luca Maurillo, Yishai Ofran, Jan Philippe, Adriana Plesa, Claude Preudhomme, Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A van de Loosdrecht, Bert A van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter J M Valk, Brent L Wood, Roland B Walter, Christian Thiede, Konstanze Döhner, Gail J Roboz, Jacqueline Cloos
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus...
December 30, 2021: Blood